english.prescrire.org > Spotlight > 100 most recent > Bedaquiline (Sirturo°) in first-line treatment for pulmonary multidrug-resistant tuberculosis

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Bedaquiline (Sirturo°) in first-line treatment for pulmonary multidrug-resistant tuberculosis

 Marketing Authorisations  During the initial evaluation of bedaquiline in patients with pulmonary multidrug-resistant tuberculosis, the main trial had shown bacteriological efficacy, but also higher mortality. Since then, several randomised trials in hundreds of patients have shown that, compared with the drug combinations previously recommended by the WHO, the use of combinations including bedaquiline make it possible to shorten the duration of treatment by several months, while providing similar bacteriological efficacy and resulting in similar mortality. 
Full article available for download by subscribers

 ©Prescrire 1 October 2025

Source: "Bedaquiline (Sirturo°) in first-line treatment for pulmonary multidrug-resistant tuberculosis" Prescrire Int 2025; 34 (274): 232-233. Subscribers only.

Filet

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook  
 
 
See also:

"Bedaquiline (Sirturo°) in pulmonary
multidrug-resistant tuberculosis
from 5 years of age"
Prescrire Int 2025;
34 (274): 234-235.
Subscribers only